Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 3/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 9/20 | 0.33 |
| ▸ | TYMP | P19971 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | MPEG1 | Q2M385 | 5/20 | 0.30 |
| ▸ | XIAP | P98170 | 2/20 | 0.30 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | PTGES | O14684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL114204 | 0.94 | ALDH1A1 (0.41) | ALDH1A1TDP1LMNAPOLBRECQL | |
| SCHEMBL7051769 | 0.92 | ALDH1A1 (0.43) | ALDH1A1TDP1LMNAPOLBRECQL | |
| SCHEMBL2947589 | 0.92 | ALDH1A1 (0.43) | ALDH1A1TDP1LMNAPOLBRECQL | |
| SCHEMBL10385817 | 0.86 | GAA (0.36) | ALDH1A1GAA | |
| Acetic Acid SCHEMBL9004863 | 0.85 | ALDH1A1 (0.44) | ALDH1A1TDP1LMNAPOLBRECQL | |
| SCHEMBL20819043 | 0.82 | ALDH1A1 (0.39) | ALDH1A1TDP1LMNAPOLBRECQL | |
| SCHEMBL17691257 | 0.81 | LMNA (0.36) | ALDH1A1TDP1LMNAPOLBRECQL | |
| SCHEMBL11800952 | 0.77 | — | — | |
| SCHEMBL11764576 | 0.76 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL8570683 | 0.75 | ALDH1A1 (0.33) | ALDH1A1TDP1LMNAPOLBRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1843 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250344991-A1 | COMPOSITIONS AND METHODS FOR A UNIVERSAL CLINICAL TEST FOR OLFACTORY DYSFUNCTION | UNIV ROCKEFELLER (US) | 2025-11-13 | — | — | US | claimed |
| US-20250325463-A1 | COMPOSITIONS (III) | SYMRISE AG (DE) | 2025-10-23 | — | — | US | claimed |
| EP-3648613-B1 | COMPOSITIONS AND METHODS FOR A UNIVERSAL CLINICAL TEST FOR OLFACTORY DYSFUNCTION | UNIV ROCKEFELLER (US) | 2025-09-24 | — | — | EP | claimed |
| US-12398341-B2 | Apparatus and compositions for improving scent delivery | THE PROCTER & GAMBLE COMPANY (US) | 2025-08-26 | — | — | US | claimed |
| EP-4602141-A1 | A FRAGRANCE MIXTURE (VI) | Symrise AG (DE) | 2025-08-20 | — | — | EP | claimed |
| CN-120130641-A | Liquid watermelon essence and preparation method and application thereof | 广州启云生物有限公司 | 2025-06-13 | — | — | CN | claimed |
| WO-2025097009-A1 | ANTIBODIES AND IMMUNOCONJUGATES FOR INDIVIDUALIZED THERAPY | NANOCARE TECHNOLOGIES, INC. (US) | 2025-05-08 | — | — | WO | claimed |
| EP-4532646-A1 | A FRAGRANCE MIXTURE (V) | Symrise AG (DE) | 2025-04-09 | — | — | EP | claimed |
| US-20250099349-A1 | A FRAGRANCE MIXTURE | SYMRISE AG (DE) | 2025-03-27 | — | — | US | claimed |
| CN-119684615-A | Crystal sponge based on column [5] arene metal organic framework, and preparation and application thereof | 浙江大学杭州国际科创中心 | 2025-03-25 | — | — | CN | claimed |
| EP-1029032-B1 | LAUNDRY TREATMENT PRODUCTS FOR SPANDEX CONTAINING FABRICS | UNILEVER PLC (GB) | 2004-03-03 | — | — | EP | claimed |
| US-20040033912-A1 | Composition for hard article surface cleaning liquid | TAKASAGO INTERNATIONAL CORPORATION | 2004-02-19 | — | — | US | claimed |
| EP-1094784-B1 | PERFUME COMPOSITION | QUEST INT (NL) | 2004-02-11 | — | — | EP | claimed |
| EP-1379229-A2 | A JASMONATE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER | RAMOT UNIVERSITY, AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. (IL) | 2004-01-14 | — | — | EP | claimed |
| US-20020193437-A1 | Mite repellant and/or miticide composition | KAO CORPORATION (JP) | 2002-12-19 | — | — | US | claimed |
| US-20020173470-A1 | JASMONATE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER | VIDAC PHARMA LTD. (IL) | 2002-11-21 | — | — | US | claimed |
| WO-2002080890-A2 | A JASMONATE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. (IL) | 2002-10-17 | — | — | WO | claimed |
| EP-1245152-A1 | Mite repellant and/or miticide composition | Kao Corporation (JP) | 2002-10-02 | — | — | EP | claimed |
| US-4304942-A | Producing substituted 2-cyclopentenones | SCM CORPORATION (US) | 1981-12-08 | — | — | US | claimed |
| US-3953514-A | Process for preparing cyclopentenone derivatives | UBE INDUSTRIES, LTD. (JA) | 1976-04-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099349-A1 | A FRAGRANCE MIXTURE | PTMS, EP300, TRPA1 | ALDH1A1 967/4885TDP1 3045/4885LMNA 2276/4885 |
| US-20020173470-A1 | JASMONATE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER | ALOX5, ALOX12, DEGS1 | ALDH1A1 1278/4885TDP1 4399/4885LMNA 3219/4885 |
| US-20250325463-A1 | COMPOSITIONS (III) | NISCH, TAS1R3, TAS2R3 | ALDH1A1 1377/4885TDP1 4022/4885LMNA 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.